{"schema_version":"secwatch.filing_event.v1","accession":"0001200375-22-000025","form_type":"8-K","ticker":"CDXS","cik":"0001200375","company_name":"CODEXIS, INC.","filed_at":"2022-07-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:55.151208+00:00","generated_at":"2026-06-24T14:48:27.906181+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Codexis cuts FY2022 revenue guidance to $135M-$141M; preliminary Q2 revenue ~$38M","bullets":["Preliminary Q2 2022 total revenue ~$38M; full-year guidance reduced to $135M-$141M.","Product revenue guidance unchanged at $112M-$118M; Pfizer product now at low end of $75M-$80M range, offset by other customers.","Gross margin on product revenue maintained at 65% to 70%.","CEO cites fewer new deals and lower-than-expected R&D revenue from existing customers as reason for reduction.","Final Q2 results to be reported on August 4, 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001200375-22-000025","json":"https://secwatch.observer/filing/0001200375-22-000025.json","markdown":"https://secwatch.observer/filing/0001200375-22-000025.md","text":"https://secwatch.observer/filing/0001200375-22-000025.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1200375/000120037522000025/0001200375-22-000025-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1200375/000120037522000025/cdxs-20220714.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T14:48:27.906181+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}